PHASE II CLINICAL STUDY AT WEILL CORNELL MEDICAL CENTER INVE

SYDNEY, Feb. 28, 2022 /PRNewswire/ – Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to...

Related Keywords

New York , United States , Australia , Memorial Sloan Kettering Cancer Center , Cornell University , Sydney , New South Wales , A Kapelnerm Vorsanger , Weill Cornell , Lew Cantley , James Garner , Anthony Fauci , Global Coalition For Adaptive Research , Genentech , Presbyterian Weill Cornell Medical Center , Weill Cornell Medical Center , National Institute Of Allergy , Oncology Consortium , Kazia Therapeutics Limited , Dana Farber Cancer Institute Harvard Medical School , St Jude Children Research Hospital , Dana Farber Cancer Institute , Kazia Therapeutics , Paxalisib Clinical Program , Alliance For Clinical Trials In Oncology , National Institutes Of Health , Phase Of Development , Weill Cornell Cancer Center , Brain Tumor Center At New York , Weill Cornell Medicine , Professor Lew Cantley , Howard Fine , Brain Tumor Center , Principal Investigator , Professor Cantley , Feil Professor , Harvard Medical School , National Institutes , Medical College , National Institute , Clinical Trials , Therapeutics Limited , Orphan Drug Designation , Fast Track Designation , Rare Pediatric Disease Designation , Orphan Designation , Chief Executive Officer , Ketogenic Diet , Cornell Cancer Center ,